AR and neoplasm: The increasing knowledge that AR-V7 expression could be a mechanism of developing castration resistance is underling the importance of targeting AR-V7 with novel therapeutic strategies when the tumor is still sensitive to ADT in order to maintain a longer state of castration sensitivity and improve patient’s outcome.